Liposomal formulations of anthracycline agents and cytidine analogs
Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.
1. A composition for parental administration to a subject which composition comprises liposomes having associated therewith daunorubicin and cytarabine, and wherein
(a) the daunorubicin and cytarabine are co-encapsulated;
(b) the daunorubicin:cytarabine mole ratio is about 1:5;
(c) the liposomes have a mean diameter of less than 250 nm; and
(d) wherein the liposomes comprise DSPC, DSPG and cholesterol in a mole ratio of about 7:2:1.
2. A method to treat a leukemia in a subject which comprises administering to said subject an effective amount of the composition of claim 1 .
3. The method of claim 2 , wherein the subject is a human.
4. The method of claim 2 , wherein the subject is a non-human mammal or avian.
5. The method of claim 3 , wherein the leukemia is ALL or AML.
6. A composition for parental administration to a subject which composition comprises liposomes having associated therewith daunorubicin and cytarabine, and wherein
(a) the daunorubicin and cytarabine are co-encapsulated;
(b) the daunorubicin:cytarabine mole ratio is about 1:5;
(c) the composition comprises no therapeutic agents in addition to the daunorubicin and cytarabine; and
(d) wherein the liposomes comprise DSPC, DSPG and cholesterol in a mole ratio of about 7:2:1.
7. A method to treat a leukemia in a subject which comprises administering to said subject an effective amount of the composition of claim 6 .
8. The method of claim 7 , wherein the subject is a human.
9. The method of claim 7 , wherein the subject is a non-human mammal or avian.
10. The method of claim 8 , wherein the leukemia is ALL or AML.